- Home
- BRIA vs FBIO Comparison
BRIA vs FBIO Comparison
Compare BRIA & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- FBIO
- Stock Information
- Founded
- BRIA 2011
- FBIO 2006
- Country
- BRIA Singapore
- FBIO United States
- Employees
- BRIA N/A
- FBIO N/A
- Industry
- BRIA
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- FBIO Health Care
- Exchange
- BRIA NYSE
- FBIO Nasdaq
- Market Cap
- BRIA 47.1M
- FBIO 49.1M
- IPO Year
- BRIA 2024
- FBIO N/A
- Fundamental
- Price
- BRIA $2.47
- FBIO $1.80
- Analyst Decision
- BRIA
- FBIO Strong Buy
- Analyst Count
- BRIA 0
- FBIO 2
- Target Price
- BRIA N/A
- FBIO $21.00
- AVG Volume (30 Days)
- BRIA 8.7K
- FBIO 229.4K
- Earning Date
- BRIA 08-15-2025
- FBIO 08-12-2025
- Dividend Yield
- BRIA N/A
- FBIO N/A
- EPS Growth
- BRIA N/A
- FBIO N/A
- EPS
- BRIA 92.24
- FBIO N/A
- Revenue
- BRIA $59,695,825.00
- FBIO $57,784,000.00
- Revenue This Year
- BRIA N/A
- FBIO $51.59
- Revenue Next Year
- BRIA N/A
- FBIO $44.74
- P/E Ratio
- BRIA $0.03
- FBIO N/A
- Revenue Growth
- BRIA 8.03
- FBIO N/A
- 52 Week Low
- BRIA $1.78
- FBIO $1.33
- 52 Week High
- BRIA $4.38
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- FBIO 49.69
- Support Level
- BRIA N/A
- FBIO $1.78
- Resistance Level
- BRIA N/A
- FBIO $2.15
- Average True Range (ATR)
- BRIA 0.00
- FBIO 0.10
- MACD
- BRIA 0.00
- FBIO -0.02
- Stochastic Oscillator
- BRIA 0.00
- FBIO 18.92
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.